Venetoclax - OmicsDI

Show results for

Unknown (1391)
Genomics (367)
Transcriptomics (209)
Proteomics (32)
Other (22)
Clinical (3)
Methylation profiling (3)
Metabolomics (3)

Organisms

Homo sapiens (257)
Mus musculus (34)
Andropogon gerardi (24)
Bacteria (24)
Canis lupus familiaris (24)
Clostridium perfringens (24)
Cnidaria (24)
Cricetulus griseus (24)
Eukaryota (24)
Fasciola (24)
Hepatitis B virus (24)
Human betaherpesvirus 5 (24)
Madurella mycetomatis (24)
Mesocricetus auratus (24)
Miscanthus x giganteus (24)
Mus musculus (24)
Mycobacterium tuberculosis (24)
Orthoflavivirus (24)
Panicum virgatum (24)
Platyhelminthes (24)
Pseudomonas aeruginosa AES-1R (24)
Rattus norvegicus (24)
Saccharomyces cerevisiae (24)
Schizosaccharomyces pombe (24)
Severe acute respiratory syndrome coronavirus 2 (24)
Shigella (24)
Sorghastrum nutans (24)
unidentified plasmid (1)
synthetic construct (1)
Macaca mulatta (1)

Organisms

Homo sapiens (230)
Mus musculus (33)
Hishimonus phycitis (1)
Macaca mulatta (1)

Repository

ENA (312)
geo (265)
pride (24)
EGA (16)
biostudies-arrayexpress (7)
MassIVE (6)
jPOST (2)
MetaboLights (2)
GNPS (1)
iProX (1)

Tissue

Cell culture (7)
B cell (4)
Bone marrow (3)
Blood (2)
Stem cell (2)
Blood cell (1)
Embryonic stem cell (1)
Epithelial cell (1)
Fibroblast (1)
Leukocyte (1)
Pancreas (1)
Spleen (1)

Disease

Acute leukemia (3)
Breast cancer (2)
Lymphoma (1)
Neoplasms (1)
Colorectal Neoplasms (1)
Acute myeloid leukemia (1)
Amyloidosis (1)
B-cell acute lymphoblastic leukemia (1)
Chronic lymphocytic leukemia (1)
Kidney cancer (1)
Lymphoma (1)

Technology Type

Mass Spectrometry (24)
Shotgun proteomics (9)
Bottom-up proteomics (8)
Data-dependent acquisition (5)
Data-independent acquisition (5)
Affinity purification coupled with mass spectrometry proteomics (2)
Mass spectrometry assay (1)
Mass spectrometry (1)
HDMSE (1)
MSE (1)
SWATH MS (1)
Top-down proteomics (1)

Instrument Platform

Q Exactive (3)
NextSeq 550 (2)
Illumina NovaSeq 6000 (2)
LTQ Orbitrap Velos (2)
Q Exactive Plus (2)
Affymetrix GCS 3000 (1)
GeneChip® Pico Kit (Affymetrix) (1)
Affymetrix Clariom™ S (400 Format) (1)
Illumina MiSeq (1)
Orbitrap Fusion (1)
Orbitrap Fusion Lumos (1)
Q Exactive HF-X (1)
Liquid Chromatography MS - alternating - c18 (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)

Publication Date

2026 (73)
2025 (59)
2024 (50)
2023 (33)
2021 (30)
2022 (28)
2019 (12)
2020 (11)
2018 (6)
2016 (2)
2017 (2)

Metabolite Name

1,2,3-Trioxolane (1)
Cyanomethyl dihydrogen phosphate (1)
2,5-dichloro-cis,cis-muconate (1)
Iron(III) citrate (1)
1,1-Dichloro-2,2-difluoroethylene (1)
Manganese(II) sulfate (MnSO4) (1)
Sodium propionate (1)
Octachlorodibenzofuran (1)
Manganese (1)
PC(5-iso PGF2VI/18:4(6Z,9Z,12Z,15Z)) (1)
Iminodicarbonsaure (1)
Peroxydicarbonic acid (1)
Cis-myrist-7-enoyl-CoA (1)
Anteisomontanyl alcohol (1)
PE(18:1(9Z)-O(12,13)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (1)
Ozone (1)
2-trans-O-Feruloylglucaric acid (1)
5,6,7,4'-Tetrahydroxyflavanone 6,7-diglucoside (1)
Carlliiionaln (1)
OCTACHLORODIBENZO-p-DIOXIN (1)
4-oxopentanoyl-CoA (1)
PC(18:1(12Z)-2OH(9,10)/15:0) (1)
TG(24:0/14:0/O-18:0) (1)
Haematin (1)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-19:0) (1)
PE(TXB2/18:1(9Z)) (1)
6-Hydroxyhexadecanoylcarnitine (1)
PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/P-16:0) (1)
TG(22:2(13Z,16Z)/18:0/O-18:0) (1)
PA(LTE4/i-16:0) (1)

First Public Date

2026 (76)
2025 (56)
2024 (56)
2023 (36)
2021 (29)
2022 (25)
2019 (14)
2020 (12)
2018 (5)
2017 (3)

Study status

Recruiting (2)
Completed (1)

Study type

Interventional (3)
Transcription profiling by array (2)
RNA-seq of coding RNA from single cells (2)
RNA-seq of coding RNA (2)
Methylation profiling by high throughput sequencing (1)

Release Date

2025 (254)
2022 (238)
2023 (222)
2021 (181)
2024 (181)
2020 (122)
2019 (67)
2026 (45)
2018 (40)
2017 (31)
2016 (11)
2015 (6)

Lab affiliation

1. Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom. 2. Department of Haematology, University of Cambridge, Cambridge, United Kingdom. 3.6. Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom. (1)
CDSS Bioanalytical Facility, Liverpool Shared Research Facilities, University of Liverpool (1)
Cambridge University (1)
Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, INSERM UMR 1050, CNRS UMR 7241, INSERM UMR 944, CNRS UMR 7212, Université de Paris, IRSL, Hôpital St. Louis Paris France (1)
Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA (1)
Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Poland (1)
Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. (1)
Department of Haematology, Cambridge Stem Cell Institute, Cambridge, UK Cambridge University Hospitals, Cambridge, UK (1)
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN (1)
Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden Institute of Molecular and Cell Biology, A*STAR, Singapore 138673, Singapor (1)
Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden Institute of Molecular and Cell Biology, A*STAR, Singapore 138673, Singapore (1)
Department of Pharmacology and Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill (1)
Department of Proteomics and Signal Transduction. (1)
Division of Blood Cells and Blood Cancer The Walter and Eliza Hall Institute of Medical Research 1G Royal Parade, Parkville Victoria, Australia, 3050 (1)
Functional Proteomics, ICR (1)
German Cancer Research Center, Heidelberg (1)
Karolinska Institutet, Department of Oncology-Pathology (OnkPat) (1)
Moffitt Cancer Center (1)
Northeastern University (1)
Program in Molecular and Integrative Physiological Sciences Harvard School of Public Health 665 Huntington Avenue Building 2, Room 221 Boston, MA 02115 USA (1)
Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA, USA (1)
Relay Therapeutics (1)
St.jude children's research hospital (1)
UCSF (1)

Location

United States (2)
Norway (1)
South Korea (1)
Spain (1)
Netherlands (1)
Australia (1)
Japan (1)

Keyword

Venetoclax (3)
Gemcitabine (2)
Bevacizumab (2)
Diffuse Large B-Cell Lymphoma (DLBCL) (1)
Non-Hodgkin lymphoma (1)
Relapsed and/or Refractory (1)
Advanced Tumors (1)
Hematological cancer (1)
Newly diagnosed (1)
Azacitidine (1)
Methotrexate (1)
Panobinostat (1)
Idelalisib (1)
Encorafinib (1)
Larotrectinib (1)
Alectinib (1)
Crizotinib (1)
Talazoparib (1)
Docetaxel (1)
Acute myeloid leukemia (AML) (1)
Dasatinib (1)
Palbociclib (1)
Metastatic Cancer (1)
Colorectal cancer (CRC) (1)
Everolimus (1)
Pembrolizumab (1)
Pertuzumab (1)
Irinotecan (1)
Trastuzumab (1)
Leucovorin (1)

Previous page
1 / 203
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 203
Next page

Sort by:

Relevance

Page size

Paired single-cell RNA-seq pre- and post-venetoclax therapy of 8 AML patients

Acute myeloid leukemia (AML) remains a cancer with dismal prognosis, particularly in high-risk disease patients and those ineligible for allogeneic stem cell transplantation. BCL-2 inhibitor venetoclax, in combination with hypomethylating agents, has emerged as an effective therapy and forms the bac...

ORGANISM(S): Homo sapiens

2025-12-31 | E-MTAB-14143 | biostudies-arrayexpress

Determinants of venetoclax resistance

PRJNA558091 | ENA

Determinants of venetoclax resistance

PRJNA558092 | ENA

Repurposing BCL2 inhibitors: Venetoclax protects against acinar cell necrosis in acute pancreatitis by promoting apoptosis

Acute pancreatitis (AP), a severe inflammatory disorder of the pancreas, lacks effective pharmacological treatment. The disease is primarily driven by necrosis of pancreatic acinar cells (PACs), which intensifies inflammation and organ injury. This study explores the potential of BCL2 inhibitors, sp...

ORGANISM(S): Mus musculus (Mouse)

2025-08-04 | PXD064881 | Pride

Effects of Navitoclax and Venetoclax on changes in the proteome of mouse pancreas in a mouse model of chronic pancreatitis

Effects of two Bcl-2 protein inhibitors Navitoclax and Venetoclax on changes in the proteome of the mouse pancreas (Mus musculus C57BL6/J, males) in a mouse model of cerulein-induced chronic pancreatitis.

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

MSV000095776 | MassIVE

Effect of venetoclax, tedizolid, and combination treatment on gene expression in a venetoclax-resistant AML cell line

PRJNA560975 | ENA

Targeting mitochondrial structure sensitizes AML to Venetoclax

PRJNA516226 | ENA

Assessing DNA methylation differences upon aquired Venetoclax resistance

PRJNA701295 | ENA

Genetic determinants of venetoclax resistance

PRJNA528105 | ENA

BCL-2 Regulation and Upstream Signal Transduction Modulate Venetoclax Resistance in Multiple Myeloma: New Avenues for Therapeutic Intervention

This study aimed to investigate the mechanisms underlying venetoclax (VTX) resistance in multiple myeloma (MM) and develop strategies to prevent or overcome resistance. VTX resistant human myeloma cell lines (HMCLs) were established and analyzed using whole exome sequencing (WES), mRNA-sequencing (m...

ORGANISM(S): Homo sapiens (Human)

2025-05-06 | PXD047149 | Pride

Venetoclax Acquired resistance Bcl-2 Proteomics Multiple myeloma

Previous page
1 / 203
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 203
Next page

Sort by:

Relevance

Page size

2030 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets